Minerva Neurosciences Inc (NERV)

1.05
0.01 0.94
NASDAQ
Prev Close 1.06
Open 1.08
Day Low/High 1.05 / 1.09
52 Wk Low/High 1.03 / 4.12
Volume 21.71K
Exchange NASDAQ
Shares Outstanding 42.72B
Market Cap 45.28M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Focus on the Trees, Not the Forest

Focus on the Trees, Not the Forest

The current market favors stock pickers.

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover

The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.

Seeing the Same Old Patterns Ahead of Fed News

Seeing the Same Old Patterns Ahead of Fed News

Buyers expect a dovish Fed and are still trying to put money to work.

Morning Movers: BIDU, WGP, NERV, INFI

Stocks were falling slightly in premarket trading Tuesday as oil continued its six-day descent.

Lack of Negative Catalyst Vexes Bears

The problem for the bears is that there are still plenty of folks trying to extract some gains from the upside.

Trending Tickers: DLTR, PSTG, NERV, USFD, TWX

Earnings reports produce mixed market reaction as stocks slip after Wednesday's rally.

Another Gem for the Biotech Basket

Another Gem for the Biotech Basket

Amid the basket's impressive performance, I'm adding Minerva.